Exelixis Inc
Symbol: EXEL (NASDAQ)
37.63
▼ (-0.20%) -0.075
Company Description:
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.
Key Stats
- Today's Open: $37.74
- Today's High: $37.74
- Today's Low: $37.45
- Today's Volume: 2.33K
- Yesterday Close: $37.7
- Yesterday High: $38.5
- Yesterday Low: $37.57
- Yesterday Volume: 2.55M
- Last Min Volume: 211
- Last Min High: $37.625
- Last Min Low: $37.625
- Last Min VWAP: $37.625
Company Profile
- Name: Exelixis Inc
- Website: https://www.exelixis.com
- Listed Date: 2000-04-11
- Location: ALAMEDA, CA
- Market Status: Active
- CIK Number: 0000939767
- SIC Code: 2836
- SIC description: BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
- Market Cap: $10.15B
- Round Lot: 100
- Outstanding Shares: 269.20M
- Asset Type: CS
RECENT FILINGS FOR EXEL
| Filing Date | Filing Type | Format |
|---|---|---|
| 2025-08-29 | 8-K | View |
| 2025-07-28 | 10-Q | View |
| 2025-07-28 | 8-K | View |
| 2025-06-04 | 4 | View |
| 2025-06-04 | 4 | View |
| 2025-06-03 | 144 | View |
| 2025-06-02 | 4 | View |
| 2025-06-02 | 144 | View |
| 2025-06-02 | 8-K | View |
| 2025-05-30 | 4 | View |
| 2025-05-30 | 4 | View |
| 2025-05-30 | 4 | View |
| 2025-05-30 | 4 | View |
| 2025-05-30 | 4 | View |
| 2025-05-30 | 4 | View |
| 2025-05-30 | 4 | View |
| 2025-05-30 | 4 | View |
| 2025-05-30 | 4 | View |
| 2025-05-22 | 4 | View |
| 2025-05-22 | 4 | View |
Latest News on EXEL